InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Fried Robert N, Chief Executive Officer. Officer active across 2 companies, notably Niagen Bioscience, Inc.. Aggregated, 5 filings have been recorded. Total volume traded: €159k. The latest transaction was disclosed on 24 April 2026 — Levée d'options. Regulator: SEC (Form 4). The full history is free.
Declarations5 total
US$44,67720,000 shares@ US$2.23380.0088% mcap100.0% of flow
Common Stock
SEC:0001417952-26-000001·
€44,67720,000 shares@ €2.23380.0088% mcap50.0% of flow
Common Stock
SEC:0001417952-26-000001:0·
€49,22825,000 shares@ €1.969130.9% of flow
Common Stock
SEC:0001628280-22-006443:0·
Ideal exit: 11 Dec 2022 (T+270)
€55,06210,000 shares@ €5.5062100.0% of flow
Common Stock
SEC:0001415889-21-002499·
Ideal exit: 7 Feb 2022 (T+270)
€55,06210,000 shares@ €5.506234.6% of flow
Common Stock
SEC:0001415889-21-002499:0·
Ideal exit: 7 Feb 2022 (T+270)
5 of 5 declarations
About Fried Robert N
Robert N. Fried is the Chief Executive Officer of Niagen Bioscience, Inc. and ChromaDex Corp. He leads these companies with a vision focused on innovation and growth.
